Newbury Pharmaceuticals AB (NEWBRY) Fair Value & Analysis
Healthcare · SE · Market cap 76.0M SEK
Fair value as of: Jul 18, 2026
From 1 valuation models · updated today
Share price +32.3% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.8000 – kr 3.31 · fair‑value band kr 0.9010 – kr 1.73 · the kr 2.50 price screens above the kr 1.39 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Newbury Pharmaceuticals AB (NEWBRY) currently trades at kr 2.50, while our model-based Fair Value estimate is kr 1.39, implying the stock looks roughly 44.2% overvalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Newbury Pharmaceuticals AB generated revenue of 32.8M SEK at a net margin of -86.9%. Revenue declined 32.0% year over year. It earns a return on equity of -74.9%. The balance sheet holds a net cash position of 15.3M SEK. Fundamentals as of Jul 18, 2026
Our scenario range runs from kr 0.9010 (bear case) to kr 1.73 (bull case); at kr 2.50, the current price sits above that range. The share trades about 24% below its 52-week high and 229% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -44%, NEWBRY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Newbury Pharmaceuticals AB reported revenue of kr 36.8M in FY2024 versus kr 2.8M in FY2021, a compound +135.2%/yr. Reported net income was −kr 20.6M in FY2025.
Is NEWBRY fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Newbury Pharmaceuticals AB (NEWBRY) undervalued?
What is the fair value of NEWBRY?
What is the quality score of NEWBRY?
What is the revenue of Newbury Pharmaceuticals AB (NEWBRY)?
What is the net profit margin of NEWBRY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Newbury Pharmaceuticals AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.